Want to see JP:4884 full AI Analyst Report?
Kringle Pharma, Inc. (4884) AI Stock Analysis
Kringle Pharma, Inc.
(TSE/TYO:4884)
The overall score is constrained by extremely weak financials and negative valuation, which are partially offset by strong bullish technical momentum. The company is unprofitable with declining revenue and significant cash burn, posing high fundamental risk. However, the stock is experiencing robust upward price trends and positive market momentum, suggesting speculative or pipeline-driven optimism.
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 268.66K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- 0.26
- Revenue Growth
- 372.42%
- EPS Growth
- 22.75%
- Country
- Japan
- Employees
- 17
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious med...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has collapsed to ¥72.2M with zero gross profit, operating losses have widened to ¥909M, and the company is burning cash from operations (¥756M outflow). Despite a debt-free balance sheet, equity has eroded significantly, and the path to profitability is unclear.
Income Statement
10Very NegativeBalance Sheet
30NegativeCash Flow
10Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.47M | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 234.20M | 72.22M | 0 | 0 | 303.42M | 218.16M |
| EBITDA | -806.45M | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -808.44M | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.70B | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 744.51M | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.25B | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -154.01M | -121.36M | -120.88M | -254.38M | 0 |
| Financing Cash Flow | 84.14M | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Neutral. The current price of 574.00 is below the 20-day moving average (MA) of 596.85, above the 50-day MA of 509.66, and above the 200-day MA of 418.75, indicating a neutral trend. The MACD of 19.17 indicates Positive momentum. The RSI at 49.41 is Neutral, neither overbought nor oversold. The STOCH value of 18.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
Overall Rating
- JP:488451Neutral
JP:457142Neutral
JP:459142Neutral
JP:458741.5Neutral
JP:459840Underperform
JP:488138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4884 | 51Neutral | JPY 4.80B | -5.05 | ― | ― | 372.42% | 22.75% |
| JP:4571 | 42Neutral | JPY 7.18B | -5.87 | -33.61% | ― | 74.24% | -7.78% |
| JP:4591 | 42Neutral | JPY 3.64B | -2.80 | ― | ― | 1135.58% | 2.37% |
| JP:4587 | 42Neutral | JPY 145.02B | -39.74 | -7.17% | ― | 0.62% | 27.66% |
| JP:4598 | 40Underperform | JPY 1.33B | -0.51 | ― | ― | ― | 20.94% |
| JP:4881 | 38Underperform | JPY 2.03B | -1.05 | ― | ― | -62.54% | 10.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4884 | Kringle Pharma, Inc. | 559.00 | 124.00 | 28.51% | |
| JP:4587 | Peptidream | 1117.00 | -414.00 | -27.04% | |
| JP:4571 | NanoCarrier Co., Ltd. | 79.00 | -79.00 | -50.00% | |
| JP:4591 | Ribomic, Inc. | 64.00 | -27.00 | -29.67% | |
| JP:4598 | Delta-Fly Pharma, Inc. | 69.00 | -350.00 | -83.53% | |
| JP:4881 | FunPep Company Limited | 40.00 | -52.00 | -56.52% |
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drug
Kringle Pharma has submitted an Investigational New Drug application to the U.S. FDA seeking to initiate a Phase 3 clinical trial of oremepermin alfa, a recombinant human hepatocyte growth factor, for the treatment of acute spinal cord injury in the...
Kringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
Kringle Pharma reported a sharp rise in net sales to ¥323 million for the nine months ended June 30, 2026, up more than fivefold year on year, but continued to post operating and net losses, with a nine-month loss of ¥631 million and a basi...
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremepermin alfa, a recombinant human hepatocyte growth factor, in patients with acute cervical spinal cord injury. The multicenter, open-label study will enroll 10 adults w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026